# Postoperative Adjuvant Therapy of HCC Based on PD-1

> **NCT05307926** · — · COMPLETED · sponsor: **Chen Xiaoping** · enrollment: 573 (actual)

## Conditions studied

- Hepatocellular Carcinoma
- RFS

## Interventions

- **DRUG:** PD-1 inhibitors
- **PROCEDURE:** TACE

## Key facts

- **NCT ID:** NCT05307926
- **Lead sponsor:** Chen Xiaoping
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2019-02-01
- **Primary completion:** 2022-07-30
- **Final completion:** 2022-08-20
- **Target enrollment:** 573 (ACTUAL)
- **Last updated:** 2022-09-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05307926

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05307926, "Postoperative Adjuvant Therapy of HCC Based on PD-1". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT05307926. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*